Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: The Swiss HIV Cohort Study

HIV Medicine

Volumn 3, Issue 4, 2002, Pages 247-253

  Bucher, H C ^a   Bichsel, M ^b   Taffe P ^c   Furrer, H ^d   Telenti, A ^c   Hirschel, B ^e   Weber, R ^f   Bernasconi, E ^g   Vernazza, P ^h   Minder, C ^b   Battegay, M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Antiretroviral therapy; HIV infections; Prospective cohort study; Protease inhibitors

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SURVIVAL; SWITZERLAND; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; VIRAL LOAD;

EID: 18744405669     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2002.00113.x     Document Type: Article

References (20)

1. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863-868.
2. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998; 338: 853-860.
3. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. Aids Clinical Trials Group 320 Study Team. N Engl J Medical 1997; 337: 725-733.
4. Kaufmann GR, Duncombe C, Cunningham P et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 1998; 12: 1625-1630.
5. Rhone SA, Hogg RS, Yip B et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998; 12: 619-624.
6. Harrigan PR, Hertogs K, Verbiest W et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir' protease inhibitor therapy in a community setting. AIDS 1999; 13: 1863-1871.
7. Cameron DW, Heath-Chiozzi M, Danner S et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1997; 351: 543-549.
8. Gisolf EH, Jurriaans S, Pelgrom J et al. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. AIDS 2000; 14: 405-413.
9. Battegay M, Vernazza PL, Bernasconi E et al. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. HIV Med 2001; 2: 35-42.
10. Kirk O, Katzenstein TL, Gerstoft J et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999; 13: F9-F16.
11. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341: 441.
12. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med 1996; 124: 999-1005.
13. Petitti DB. Hormone replacement therapy and heart disease prevention: experimentation trumps observation. JAMA 1998; 280: 650-652.
14. Ioannidis JP, Haidich AB, Pappa M et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821-830.
15. Cameron DW, Japour A, Xu Y et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13: 213-224.
16. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr 2001; 27: 350-364.
17. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS 2001; 15: 1679-1686.
18. Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA 2001; 285: 777-784.
19. Hansel A, Bucher HC, Nuesch R, Battegay M. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr 2001; 26: 191-193.
20. Fellay J, Boubaker K, Ledergerber B et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-1327.